Glasgow-based biopharmaceutical firm Mironid has successfully closed a €39.9 million ($46 million) Series B financing round to advance its leading drug candidate for a common genetic kidney disease. The funding, led by the Scottish National Investment Bank, will propel the company's first-in-class treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. This significant investment underscores strong confidence in Mironid's innovative approach to tackling degenerative and rare diseases.
Strong Syndicate Backing
The financing round saw the Scottish National Investment Bank join a robust syndicate of Mironid's existing investors, highlighting sustained belief in the company's mission. This group includes prominent names such as the Roche Venture Fund, Epidarex Capital, Sofinnova Partners, and BioGeneration Ventures. The continued participation of these high-caliber backers serves as a powerful validation of Mironid's scientific platform and development strategy.
Paul Callaghan, Investment Director at the Scottish National Investment Bank, noted that Mironid exemplifies Scotland's growing reputation for biotech innovation. He expressed pleasure in joining a committed group of investors to support the company through this critical stage of growth. The investment aims to help translate world-class research into tangible clinical progress and potential patient benefits.
Addressing a Critical Unmet Need
Autosomal Dominant Polycystic Kidney Disease is the most common hereditary kidney disorder, affecting over 12 million people globally. The disease is characterized by the uncontrolled growth of fluid-filled cysts in the kidneys, which often leads to severe complications. Tragically, approximately half of all patients with ADPKD will develop kidney failure by the age of 60, creating an urgent need for more effective treatments.
An Innovative Therapeutic Strategy
Mironid's lead candidate is a first-in-class LoAc small molecule designed to directly target a cellular signal known as cyclic AMP (cAMP). This signal is a key driver of both cell proliferation and fluid secretion within the cysts at all stages of the disease. By modulating cAMP, Mironid's approach aims to address the root cause of cyst formation and growth.
Preclinical data has demonstrated significant efficacy and a favorable safety profile for the company's LoAc molecules across key disease endpoints. The treatment has shown the potential to reduce both cyst number and overall kidney volume. Mironid believes this unique mechanism could offer a more durable treatment with an improved side-effect profile compared to existing therapies.
From Academic Research to Clinical Application
Mironid was established in 2015 as a spin-out from the University of Strathclyde and Heriot-Watt University. The company's foundation is built upon more than three decades of pioneering research into PDE biology by Professor Miles Houslay. This strong academic heritage provides a deep scientific basis for its drug development programs.
While its immediate focus is on ADPKD, Mironid's broader pipeline targets phosphodiesterase 4 (PDE4) enzymes. These enzymes play a crucial role in cell signaling pathways implicated in major inflammatory diseases and cancer. This wider scope demonstrates the potential of the company's platform to address multiple serious conditions.
Fueling Clinical Advancement
The proceeds from the Series B financing will be strategically allocated to advance the clinical development of the company's lead ADPKD candidate. According to CEO Neil Wilkie, this funding is essential for progressing the program and moving closer to transforming the treatment landscape for patients. The capital injection marks a pivotal moment in the company's journey toward commercialization.
This substantial €39.9 million investment marks a significant milestone for Mironid, enabling the company to accelerate its promising treatment for ADPKD into the clinical phase. The strong backing from a syndicate of esteemed investors not only validates its innovative scientific approach but also reinforces Scotland's position as a hub for biotech excellence. Ultimately, this development offers renewed hope for millions of patients worldwide living with this debilitating genetic kidney disease.